Search

Displaying results 3121 - 3130 of 10000 in total
  1. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    Pruritus associated with chronic kidney disease (also called uremic pruritus) affects 50-60% of all patients on dialysis and 25% of non-dialysis patients with chronic kidney disease. … [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]

  2. Drug

    Carprofen

    go.drugbank.com/drugs/DB00821
    ApprovedVet approvedWithdrawn

    Carprofen was previously used in human medicine for over 10 years (1985-1995). … It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory

  3. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

  4. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … It promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- yl
  5. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to

  6. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

  7. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. … Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates

  8. Indication

    Enuresis

    go.drugbank.com/conditions/DBCOND0018540
    Drugs: Imipramine
    Synonyms: Enuresis not due to a substance or known physiological condition
  9. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    produces proteins unresponsive to ivacaftor or tezacaftor. … [A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.

    Synonyms: L-5-MTHF, (6S)-5-MTHFMixtures: Medi-10, TL-Folate